Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs)

References

• Diamantis N, Banerji U. Antibody-drug conjugates–an emerging class of cancer treatment. Br J Cancer. 2016;114:362–7. doi:10.1038/bjc.2015.435.
   PubMed Web of Science ®Google Scholar
• McGranahan N, Swanton C. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell. 2015;27:15–26. doi:10.1016/j.ccell.2014.12.001.
   PubMed Web of Science ®Google Scholar
• Peters C, Brown S. Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep. 2015;35:e00225. doi:10.1042/BSR20150089. PMID:26182432
   PubMed Web of Science ®Google Scholar
• Ritchie M, Tchistiakova L, Scott N. Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates. MAbs. 2013;5:13–21. doi:10.4161/mabs.22854.
   PubMed Web of Science ®Google Scholar
• Stenmark H. Rab GTPases as coordinators of vesicle traffic. Nat Rev Mol Cell Biol. 2009;10:513–25. doi:10.1038/nrm2728.
   PubMed Web of Science ®Google Scholar
• Lu J, Jiang F, Lu A, Zhang G. Linkers Having a Crucial Role in Antibody-Drug Conjugates. Int J Mol Sci. 2016;17:561. doi:10.3390/ijms17040561. PMID:26182432
   PubMed Web of Science ®Google Scholar
• Kim EG, Kim KM. Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics. Biomol Ther (Seoul). 2015;23:493–509. doi:10.4062/biomolther.2015.116.
   PubMed Web of Science ®Google Scholar
• Jain N, Smith SW, Ghone S, Tomczuk B. Current ADC linker chemistry. Pharm Res. 2015;32:3526–40. doi:10.1007/s11095-015-1657-7.
   PubMed Web of Science ®Google Scholar
• Singh AP, Sharma S, Shah DK. Quantitative characterization of in vitro bystander effect of antibody-drug conjugates. J Pharmacokinet Pharmacodyn. 2016;43:567–82. doi:10.1007/s10928-016-9495-8.
   PubMed Web of Science ®Google Scholar
• Perrino E, Steiner M, Krall N, Bernardes GJL, Pretto F, Casi G, Neri D. Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids. Cancer Res. 2014;74:2569–78. doi:10.1158/0008-5472.CAN-13-2990.
   PubMed Web of Science ®Google Scholar
• Okeley NM, Miyamoto JB, Zhang X, Sanderson RJ, Benjamin DR, Sievers EL, Senter PD, Alley SC. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res. 2010;16:888–97. doi:10.1158/1078-0432.CCR-09-2069.
   PubMed Web of Science ®Google Scholar
• Beck A, Haeuw J-F, Wurch T, Goetsch L, Bailly C, Corvaïa N. The Next Generation of Antibody-drug Conjugates Comes of Age. Discov Med. 2010;10:329–39. PMID:26182432
   PubMed Web of Science ®Google Scholar
• Pfizer. PFIZER RECEIVES FDA APPROVAL FOR MYLOTARG™ (GEMTUZUMAB OZOGAMICIN) [Internet]. 2017 [cited 2017 Sep 9]; Available from: http://www.pfizer.com/news/press-release/press-release-detail/pfizer_receives_fda_approval_for_mylotarg_gemtuzumab_ozogamicin
   Google Scholar
• Hills RK, Castaigne S, Appelbaum FR, Delaunay J, Petersdorf S, Othus M, Estey EH, Dombret H, Chevret S, Ifrah N, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 2014;15:986–96. doi:10.1016/S1470-2045(14)70281-5.
   PubMed Web of Science ®Google Scholar
• Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363:1812–21. doi:10.1056/NEJMoa1002965.
   PubMed Web of Science ®Google Scholar
• Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh D-Y, Diéras V, Guardino E, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783–91. doi:10.1056/NEJMoa1209124.
   PubMed Web of Science ®Google Scholar
• Pfizer. BESPONSA® Approved in the EU for Adult Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia [Internet]. 2017 [cited 2017 Aug 4]; Available from: http://press.pfizer.com/press-release/besponsa-approved-eu-adult-patients-relapsed-or-refractory-b-cell-precursor-acute-lymp
   Google Scholar
• Beck A, Reichert JM. Antibody-drug conjugates. MAbs. 2014;6:15–7. doi:10.4161/mabs.27436.
   PubMed Web of Science ®Google Scholar
• Ponte JF, Ab O, Lanieri L, Lee J, Coccia J, Bartle LM, Themeles M, Zhou Y, Pinkas J, Ruiz-Soto R. Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models. Neoplasia. 2016;18:775–84. doi:10.1016/j.neo.2016.11.002.
   PubMed Web of Science ®Google Scholar
• Seattle Genetics. Vadastuximab Talirine discontinued [Internet]. VADASTUXIMAB TALIRINE2017 [cited 2017 Aug 15]; Available from: http://www.seattlegenetics.com/pipeline/vadastuximab-talirine
   Google Scholar
• Kung Sutherland MS, Walter RB, Jeffrey SC, Burke PJ, Yu C, Kostner H, Stone I, Ryan MC, Sussman D, Lyon RP, et al. SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood. 2013;122:1455–63. doi:10.1182/blood-2013-03-491506.
   PubMed Web of Science ®Google Scholar
• Rossi A. Rovalpituzumab tesirine and DLL3: a new challenge for small-cell lung cancer. Lancet Oncol. 2017;18:3–5. doi:10.1016/S1470-2045(16)30575-7.
   PubMed Web of Science ®Google Scholar
• Beck A, Goetsch L, Dumontet C, Corvaïa N. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16:315–37. doi:10.1038/nrd.2016.268.
   PubMed Web of Science ®Google Scholar
• Cardillo TM, Govindan SV, Sharkey RM, Trisal P, Arrojo R, Liu D, Rossi EA, Chang C-H, Goldenberg DM. Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers. Bioconjug Chem. 2015;26:919–31. doi:10.1021/acs.bioconjchem.5b00223.
   PubMed Web of Science ®Google Scholar
• Miller ML, Fishkin NE, Li W, Whiteman KR, Kovtun Y, Reid EE, Archer KE, Maloney EK, Audette CA, Mayo MF, et al. A New Class of Antibody-Drug Conjugates with Potent DNA Alkylating Activity. Mol Cancer Ther. 2016;15:1870–8. doi:10.1158/1535-7163.MCT-16-0184.
   PubMed Web of Science ®Google Scholar
• Lambert JM, Chari RVJ. Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer. J Med Chem. 2014;57:6949–64. doi:10.1021/jm500766w.
   PubMed Web of Science ®Google Scholar
• Haddley K. Brentuximab vedotin: its role in the treatment of anaplastic large cell and Hodgkin's lymphoma. Drugs Today. 2012;48:259–70. doi:10.1358/dot.2012.48.4.1788435.
   PubMed Web of Science ®Google Scholar
• Damelin M, Zhong W, Myers J, Sapra P. Evolving Strategies for Target Selection for Antibody-Drug Conjugates. Pharm Res. 2015;32:3494–507. doi:10.1007/s11095-015-1624-3.
   PubMed Web of Science ®Google Scholar
• Fisher R, Pusztai L, Swanton C. Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer. 2013;108:479–85. doi:10.1038/bjc.2012.581.
   PubMed Web of Science ®Google Scholar
• Kovtun YV, Audette CA, Ye Y, Xie H, Ruberti MF, Phinney SJ, Leece BA, Chittenden T, Blättler WA, Goldmacher VS. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res. 2006;66:3214–21. doi:10.1158/0008-5472.CAN-05-3973.
   PubMed Web of Science ®Google Scholar
• Dornan D, Bennett F, Chen Y, Dennis M, Eaton D, Elkins K, French D, Go MAT, Jack A, Junutula JR, et al. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood. 2009;114:2721–9. doi:10.1182/blood-2009-02-205500.
   PubMed Web of Science ®Google Scholar
• Boyiadzis M, Foon KA. Approved monoclonal antibodies for cancer therapy. Expert Opin Biol Ther. 2008;8:1151–8. doi:10.1517/14712598.8.8.1151.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Hauler F, Dziunycz P, Schwager K, Soltermann A, Pretto F, Alonso C, Hofbauer GF, Boyle RW, Neri D. A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels. Br J Cancer. 2011;104:1106–15. doi:10.1038/bjc.2011.78.
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Richardson AM, Rodriguez-Canales J, Ylaya K, Erickson HS, Player A, Kawasaki ES, Pinto PA, Choyke PL, Merino MJ, et al. Identification of EpCAM as a molecular target of prostate cancer stroma. Am J Pathol. 2009;175:2277–87. doi:10.2353/ajpath.2009.090013.
   PubMed Web of Science ®Google Scholar
• Hofmeister V, Schrama D, Becker JC. Anti-cancer therapies targeting the tumor stroma. Cancer Immunol Immunother. 2008;57:1–17. doi:10.1007/s00262-007-0365-5.
   PubMed Web of Science ®Google Scholar
• Mack F, Ritchie M, Sapra P. The next generation of antibody drug conjugates. Semin Oncol. 2014;41:637–52. doi:10.1053/j.seminoncol.2014.08.001.
   PubMed Web of Science ®Google Scholar
• Hurwitz E, Stancovski I, Sela M, Yarden Y. Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake. Proc Natl Acad Sci U S A. 1995;92:3353–7. doi:10.1073/pnas.92.8.3353.
   PubMed Web of Science ®Google Scholar
• de Goeij BE, Lambert JM. New developments for antibody-drug conjugate-based therapeutic approaches. Curr Opin Immunol. 2016;40:14–23. doi:10.1016/j.coi.2016.02.008.
   PubMed Web of Science ®Google Scholar
• Sauter A, Kloft C, Gronau S, Bogeschdorfer F, Erhardt T, Golze W, Schroen C, Staab A, Riechelmann H, Hoermann K. Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck. Int J Oncol. 2007;30:927–35. doi:10.3892/ijo.30.4.927.
   PubMed Web of Science ®Google Scholar
• Rupp U, Schoendorf-Holland E, Eichbaum M, Schuetz F, Lauschner I, Schmidt P, Staab A, Hanft G, Huober J, Sinn H-P, et al. Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study. Anticancer Drugs. 2007;18:477–85. doi:10.1097/CAD.0b013e32801403f4.
   PubMed Web of Science ®Google Scholar
• Polson AG, Ho WY, Ramakrishnan V. Investigational antibody-drug conjugates for hematological malignancies. Expert Opin Investig Drugs. 2011;20:75–85. doi:10.1517/13543784.2011.539557.
   PubMed Web of Science ®Google Scholar
• Smith LM, Nesterova A, Alley SC, Torgov MY, Carter PJ. Potent cytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressing melanotransferrin/p97. Mol Cancer Ther. 2006;5:1474–82. doi:10.1158/1535-7163.MCT-06-0026.
   PubMed Web of Science ®Google Scholar
• Wang X, Ma D, Olson WC, Heston WDW. In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen. Mol Cancer Ther. 2011;10:1728–39. doi:10.1158/1535-7163.MCT-11-0191.
   PubMed Web of Science ®Google Scholar
• Panowksi S, Bhakta S, Raab H, Polakis P, Junutula JR. Site-specific antibody drug conjugates for cancer therapy. MAbs. 2014;6:34–45. doi:10.4161/mabs.27022.
   PubMed Web of Science ®Google Scholar
• Wakankar A, Chen Y, Gokarn Y, Jacobson FS. Analytical methods for physicochemical characterization of antibody drug conjugates. MAbs. 2011;3:161–72. doi:10.4161/mabs.3.2.14960.
   PubMed Web of Science ®Google Scholar
• Agarwal P, Bertozzi CR. Site-specific antibody-drug conjugates: the nexus of bioorthogonal chemistry, protein engineering, and drug development. Bioconjug Chem. 2015;26:176–92. doi:10.1021/bc5004982.
   PubMed Web of Science ®Google Scholar
• Liu H, May K. Disulfide bond structures of IgG molecules: structural variations, chemical modifications and possible impacts to stability and biological function. MAbs. 2012;4:17–23. doi:10.4161/mabs.4.1.18347.
   PubMed Web of Science ®Google Scholar
• Schumacher FF, Nunes JPM, Maruani A, Chudasama V, Smith MEB, Chester KA, Baker JR, Caddick S. Next generation maleimides enable the controlled assembly of antibody-drug conjugates via native disulfide bond bridging. Org Biomol Chem. 2014;12:7261–9. doi:10.1039/C4OB01550A.
   PubMed Web of Science ®Google Scholar
• Lyon RP, Bovee TD, Doronina SO, Burke PJ, Hunter JH, Neff-LaFord HD, Jonas M, Anderson ME, Setter JR, Senter PD. Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index. Nat Biotechnol. 2015;33:733–5. doi:10.1038/nbt.3212.
   PubMed Web of Science ®Google Scholar
• Hamblett KJ, Senter PD, Chace DF, Sun MMC, Lenox J, Cerveny CG, Kissler KM, Bernhardt SX, Kopcha AK, Zabinski RF, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res. 2004;10:7063–70. doi:10.1158/1078-0432.CCR-04-0789.
   PubMed Web of Science ®Google Scholar
• Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, Chen Y, Simpson M, Tsai SP, Dennis MS, et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol. 2008;26:925–32. doi:10.1038/nbt.1480.
   PubMed Web of Science ®Google Scholar
• Junutula JR, Flagella KM, Graham RA, Parsons KL, Ha E, Raab H, Bhakta S, Nguyen T, Dugger DL, Li G, et al. Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Clin Cancer Res. 2010;16:4769–78. doi:10.1158/1078-0432.CCR-10-0987.
   PubMed Web of Science ®Google Scholar
• Shen B-Q, Xu K, Liu L, Raab H, Bhakta S, Kenrick M, Parsons-Reponte KL, Tien J, Yu S-F, Mai E, et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol. 2012;30:184–9. doi:10.1038/nbt.2108.
   PubMed Web of Science ®Google Scholar
• Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012;12:278–87. doi:10.1038/nrc3236.
   PubMed Web of Science ®Google Scholar
• Junttila TT, Li G, Parsons K, Phillips GL, Sliwkowski MX. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat. 2011;128:347–56. doi:10.1007/s10549-010-1090-x.
   PubMed Web of Science ®Google Scholar
• Weiskopf K, Weissman IL. Macrophages are critical effectors of antibody therapies for cancer. MAbs. 2015;7:303–10. doi:10.1080/19420862.2015.1011450.
   PubMed Web of Science ®Google Scholar
• Gong Q, Ou Q, Ye S, Lee WP, Cornelius J, Diehl L, Lin WY, Hu Z, Lu Y, Chen Y, et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol. 2005;174:817–26. doi:10.4049/jimmunol.174.2.817.
   PubMed Web of Science ®Google Scholar
• Uppal H, Doudement E, Mahapatra K, Darbonne WC, Bumbaca D, Shen B-Q, Du X, Saad O, Bowles K, Olsen S, et al. Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1). Clin Cancer Res. 2015;21:123–33. doi:10.1158/1078-0432.CCR-14-2093.
   PubMed Web of Science ®Google Scholar
• Zhao H, Gulesserian S, Ganesan SK, Ou J, Morrison K, Zeng Z, Robles V, Snyder J, Do L, Aviña H, et al. Inhibition of Megakaryocyte Differentiation by Antibody-Drug Conjugates (ADCs) is Mediated by Macropinocytosis: Implications for ADC-induced Thrombocytopenia. Mol Cancer Ther. 2017;16:1877–86. doi:10.1158/1535-7163.MCT-16-0710.
   PubMed Web of Science ®Google Scholar
• Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014;5:520. doi:10.3389/fimmu.2014.00520. PMID:26182432
   PubMed Web of Science ®Google Scholar
• Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, Daëron M. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood. 2009;113:3716–25. doi:10.1182/blood-2008-09-179754.
   PubMed Web of Science ®Google Scholar
• Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol. 2006;6:343–57. doi:10.1038/nri1837.
   PubMed Web of Science ®Google Scholar
• Wiggins B, Liu-Shin L, Yamaguchi H, Ratnaswamy G. Characterization of cysteine-linked conjugation profiles of immunoglobulin G1 and immunoglobulin G2 antibody-drug conjugates. J Pharm Sci. 2015;104:1362–72. doi:10.1002/jps.24338.
   PubMed Web of Science ®Google Scholar
• Doñate F, Raitano A, Morrison K, An Z, Capo L, Aviña H, Karki S, Morrison K, Yang P, Ou J, et al. AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma. Clin Cancer Res. 2016;22:1989–99. doi:10.1158/1078-0432.CCR-15-1542.
   PubMed Web of Science ®Google Scholar
• Carter PJ, Senter PD. Antibody-drug conjugates for cancer therapy. Cancer J. 2008;14:154–69. doi:10.1097/PPO.0b013e318172d704.
   PubMed Web of Science ®Google Scholar
• Crescioli S, Correa I, Karagiannis P, Davies AM, Sutton BJ, Nestle FO, Karagiannis SN. IgG4 Characteristics and Functions in Cancer Immunity. Curr Allergy Asthma Rep. 2016;16:7. doi:10.1007/s11882-015-0580-7. PMID:26182432
   PubMed Web of Science ®Google Scholar
• Labrijn AF, Rispens T, Meesters J, Rose RJ, Bleker TH den, Loverix S, van den Bremer ETJ, Neijssen J, Vink T, Lasters I, et al. Species-specific determinants in the IgG CH3 domain enable Fab-arm exchange by affecting the noncovalent CH3-CH3 interaction strength. J Immunol. 2011;187:3238–46. doi:10.4049/jimmunol.1003336.
   PubMed Web of Science ®Google Scholar
• Davies AM, Rispens T, Bleker TH den, McDonnell JM, Gould HJ, Aalberse RC, Sutton BJ. Crystal structure of the human IgG4C(H)3 dimer reveals the role of Arg409 in the mechanism of Fab-arm exchange. Mol Immunol. 2013;54:1–7. doi:10.1016/j.molimm.2012.10.029.
   PubMed Web of Science ®Google Scholar
• Bruggeman CW, Dekkers G, Bentlage AEH, Treffers LW, Nagelkerke SQ, Lissenberg-Thunnissen S, Koeleman CAM, Wuhrer M, van den Berg TK, Rispens T, et al. Enhanced effector functions due to antibody defucosylation depend on the effector cell fcγ receptor profile. J Immunol. 2017;199:204–11. doi:10.4049/jimmunol.1700116.
   PubMed Web of Science ®Google Scholar
• Tai Y-T, Mayes PA, Acharya C, Zhong MY, Cea M, Cagnetta A, Craigen J, Yates J, Gliddon L, Fieles W, et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014;123:3128–38. doi:10.1182/blood-2013-10-535088.
   PubMed Web of Science ®Google Scholar
• Stopforth RJ, Cleary KLS, Cragg MS. Regulation of monoclonal antibody immunotherapy by fcγriib. J Clin Immunol. 2016;36 Suppl 1:88–94. doi:10.1007/s10875-016-0247-8.
   PubMedGoogle Scholar
• Strohl WR. Current progress in innovative engineered antibodies. Protein Cell. 2017;. doi:10.1007/s13238-017-0457-8. PMID:26182432
   PubMed Web of Science ®Google Scholar
• Vafa O, Gilliland GL, Brezski RJ, Strake B, Wilkinson T, Lacy ER, Scallon B, Teplyakov A, Malia TJ, Strohl WR. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations. Methods. 2014;65:114–26. doi:10.1016/j.ymeth.2013.06.035.
   PubMed Web of Science ®Google Scholar
• Dall'Acqua WF, Kiener PA, Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem. 2006;281:23514–24. doi:10.1074/jbc.M604292200.
   PubMed Web of Science ®Google Scholar
• Hamblett KJ, Le T, Rock BM, Rock DA, Siu S, Huard JN, Conner KP, Milburn RR, O'Neill JW, Tometsko ME, et al. Altering Antibody-Drug Conjugate Binding to the Neonatal Fc Receptor Impacts Efficacy and Tolerability. Mol Pharm. 2016;13:2387–96. doi:10.1021/acs.molpharmaceut.6b00153.
   PubMedGoogle Scholar
• Han TH, Zhao B. Absorption, distribution, metabolism, and excretion considerations for the development of antibody-drug conjugates. Drug Metab Dispos. 2014;42:1914–20. doi:10.1124/dmd.114.058586.
   PubMedGoogle Scholar
• Perez HL, Cardarelli PM, Deshpande S, Gangwar S, Schroeder GM, Vite GD, Borzilleri RM. Antibody-drug conjugates: current status and future directions. Drug Discov Today. 2014;19:869–81. doi:10.1016/j.drudis.2013.11.004.
   PubMed Web of Science ®Google Scholar
• Scott AM, Lee F-T, Tebbutt N, Herbertson R, Gill SS, Liu Z, Skrinos E, Murone C, Saunder TH, Chappell B, et al. A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc Natl Acad Sci U S A. 2007;104:4071–6. doi:10.1073/pnas.0611693104.
   PubMed Web of Science ®Google Scholar
• Teicher BA, Chari RVJ. Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res. 2011;17:6389–97. doi:10.1158/1078-0432.CCR-11-1417.
   PubMed Web of Science ®Google Scholar
• Schmidt MM, Wittrup KD. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther. 2009;8:2861–71. doi:10.1158/1535-7163.MCT-09-0195.
   PubMed Web of Science ®Google Scholar
• Kim KM, McDonagh CF, Westendorf L, Brown LL, Sussman D, Feist T, Lyon R, Alley SC, Okeley NM, Zhang X, et al. Anti-CD30 diabody-drug conjugates with potent antitumor activity. Mol Cancer Ther. 2008;7:2486–97. doi:10.1158/1535-7163.MCT-08-0388.
   PubMed Web of Science ®Google Scholar